DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01695109

CompletedPhase 4

The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

16

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 19-25•Male•Healthy volunteers

Primary endpoints

•Food intake at an ad libitum buffet•FMRI activity in the brain

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01695109
Org study ID702/2008

Timeline

Milestones

Study first posted2012-09-27estimated
Last update posted2012-09-27estimated
Study start2010-11 (month precision)
Primary completion2012-02actual (month precision)
Study completion2012-03actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age40 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Male healthy volunteers
•Age 20-40
•Non-smokers
•Normal body weight (body mass index 19 -25 kg/m2)
•Right handed
•Signed informed consent
•Willingness and ability to comply with the protocol

Exclusion criteria

•Any history of or current drug abuse including alcohol consumption on a regular basis or binge drinking
•Any history of or current psychiatric disease, including any eating disorder, as assessed by structured interview
•Any history of dieting
•Any condition interfering with fMRI measurements such as ferromagnetic implants or claustrophobia
•Any evidence of relevant renal, liver, thyroid, cardiovascular, or respiratory illness at screening examination
•Any acute illness necessitating medical treatment during the last 3 weeks before study entry, any permanent intake of medication
•Any study participation in the last 3 months
•HIV, hepatitis B or C positive
•Any disease considered relevant for proper performance of the study or risks to the participant, at the discretion of the investigator

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Glycemic / diabetes
1
Patient-reported / QoL
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Changes in Ghrelin, PYY, glucose and insulin concentrations during the study session

Time frame:timepoints -10, 90, 130 minutes

concentration, descriptive

componentsFasting glucose, change, HOMA-IR (insulin sensitivity)

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Changes in hunger and satiety scores on the visual analogue scales (VAS) over time as compared to baseline (measured in mm) during the study session

Time frame:timepoints -10, 90, 130 minutes

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Food intake at an ad libitum buffet

Time frame:day 4

descriptive

Primary/protocol endpoint/low confidence

fMRI activity in the brain

Time frame:day 4

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.